Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10 6월 2023 - 5:01AM
Business Wire
Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that the Compensation Committee of the company’s Board of
Directors granted four employees nonqualified stock options to
purchase 308,000 shares of its common stock with an exercise price
of $3.06 per share, which is equal to the closing price of Kezar’s
common stock on June 6, 2023, the grant date of the awards. The
stock options were granted as an inducement award material to the
individuals entering into employment with Kezar, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The stock options will vest over a four-year period, with 25% of
each option vesting on the first anniversary of the employee’s
start date, and 1/48th of the total shares vesting monthly
thereafter, subject to continued employment on each vesting date.
The options are subject to the terms and conditions of Kezar’s 2022
Inducement Plan and the stock option agreement covering the
grants.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing novel treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor that
has completed a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230609005379/en/
Investor Contact: Gitanjali Jain Vice President, Investor
Relations and External Affairs gjain@kezarbio.com Media
Contact: Julia Deutsch Solebury Strategic Communications
jdeutsch@soleburystrat.com
Kezar Life Sciences (NASDAQ:KZR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Kezar Life Sciences (NASDAQ:KZR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024